Prior to joining Augustine, she served as the Chief Scientific Officer at Aelin Therapeutics, where she played a key role in developing a degrader platform based on induced protein aggregation to ...

Virginie Cartage, the newly appointed CFO of Augustine Therapeutics commented: “It is a very exciting time to be joining the Augustine team as there is a real sense of momentum in the business.

In addition, Augustine today announced the founding of a Copenhagen, Denmark based subsidiary, Augustine Therapeutics Denmark ApS, which will serve as the company's hub for research related to ...

New recruits expand senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the treatment of Charcot-Marie-Tooth disease LEUVEN, Belgium – ...